Stockreport

Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome [Yahoo! Finance]

Neurogene Inc.  (NGNE) 
PDF Expect to complete trial enrollment in three to six months Neurogene management to present Phase 1/2 interim data update at Stifel Healthcare Conference on November 1 [Read more]